Table 2.

MSQ-RFR Responders by Treatment Group

Treatment	na	Response Rate (%)	Odds Ratiob (95% CI)	P-valuec
PBO	228	11.8	-	-
GMB 120 mg	112	25.0	2.86 (1.33–6.17)	0.008
GMB 240 mg	112	25.9	3.91 (1.89–8.10)	<0.001

Notes: ^an = number of intent-to-treat subjects who have non-missing baseline values and ≥1 post-baseline value at Month 4, 5, or 6; ^bVs PBO; ^cP-values from logistic regression: responder indicator = treatment, baseline, and baseline number of monthly migraine headache days (<8, ≥8). Responders were defined as patients whose change from baseline to average of Months 4–6 in the MSQ-RFR domain was ≥25.

Abbreviations: CI, confidence interval; GMB, galcanezumab; MSQ-RFR, Migraine-Specific Quality-of-Life Questionnaire Role Function-Restrictive domain; PBO, placebo.